Drug intelligence / Profile preview

RKER-216

Development stage: Preclinical
Lead developer: Keros Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

RKER-216 is an investigational neutralizing antibody developed by Keros Therapeutics. It targets Activin receptor-like kinase 2 (ALK2) to suppress hepcidin production, thereby increasing iron availability for erythropoiesis. It is being investigated for the treatment of anemia of inflammation, particularly in the context of chronic kidney disease. Preclinical studies have demonstrated that RKER-216 can improve hemoglobin and red blood cell production, both as a monotherapy and in combination with KER-050.

Targets

ACVR1 (Activin receptor type I)

Beyond the preview

Go deeper on RKER-216.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RKER-216.

Explore the full profile